The physiological function of NPC1L1 is selectively inhibited by ezetimibe, a globally used lipid‐lowering drug.9 While large clinical studies have been conducted to evaluate the efficacy of ezetimibe in dyslipidemia therapy,10, 11 little information is available regarding the therapeutic effect of ezetimibe on human NAFLD. This evidence concerns the gene NPC1L1 and metabolic syndrome.